Iowanews Headlines

Biopsy Devices Market

The global biopsy devices market is projected to grow at a CAGR of 5.1% from 2025 to 2032. Key factors driving this growth include the rising prevalence of breast cancer, an expanding elderly population, increasing lung cancer cases, and ongoing technological advancements in biopsy devices. As a result, the market is expected to witness consistent expansion throughout the forecast period.

DelveInsight’s Biopsy Devices Market Insights report offers a comprehensive analysis of the current and projected market, including market shares of leading companies, key drivers, challenges, trends, barriers, and notable players in the biopsy devices sector.

Request for a sample report: https://www.delveinsight.com/report-store/biopsy-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:

• In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).

• In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.

• In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).

• In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.

• In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.

• In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER™ program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.

• In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.

• In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.

Key Takeaways from the Biopsy Devices Market Report

• The Biopsy Devices market is expected to expand at a moderate CAGR between 2025 and 2032.

• According to DelveInsight, North America is projected to hold the largest share of the global Biopsy Devices market during the forecast period.

The Biopsy Devices market is a rapidly evolving sector within healthcare, playing a crucial role in diagnosing and managing a wide range of medical conditions. It encompasses various types of biopsy instruments, including needle-based biopsy tools, core biopsy systems, and vacuum-assisted biopsy devices, among others.

Prominent companies operating in the Biopsy Devices market include Boston Scientific Corporation, Cardinal Health, Medtronic, BD, Cook, Devicor Medical Products Inc, B. Braun Melsungen AG, ARGON MEDICAL, OLYMPUS CORPORATION, FUJIFILM, INRAD Inc, Hologic Inc, C. R. Bard, Dr. Japan Co Ltd, Limaca Medical, Owlstone Medical Ltd, Zamar Care, KOELIS, ST. STONE MEDICAL DEVICES PVT LTD, Iscon Surgicals Ltd, and others.

Key developments include:

• In May 2022, Limaca Medical, an Israeli company specializing in enhancing endoscopic biopsy outcomes for gastrointestinal tumors, received FDA breakthrough device designation for its Precision GI endoscopic ultrasound biopsy device, which is operated via the endoscope’s instrument channel to sample tumors.

• In the same month, Limaca Medical partnered with HekaBio K.K., a Tokyo-based healthcare company, to distribute the Precision GI Endoscopic Biopsy Device in Japan.

• In July 2019, FUJIFILM Medical Systems U.S.A., Inc. introduced the Tomosynthesis Biopsy option for its ASPIRE Cristalle mammography system. This addition uses tomosynthesis guidance to determine 3D coordinates of suspicious breast lesions, enabling precise biopsies for diagnosis and treatment planning.

To read more about the latest highlights related to the Biopsy Devices market, get a snapshot of the key highlights entailed in the Global Biopsy Devices Market Report

Biopsy Devices Overview

Biopsy devices are vital in medical diagnostics, allowing clinicians to obtain tissue samples for the detection and diagnosis of diseases such as cancer and infections. The market comprises a range of instruments, including needle biopsy devices, core biopsy systems, and vacuum-assisted biopsy tools, each tailored to specific procedures and clinical requirements. These devices are crucial for delivering accurate, minimally invasive diagnostic solutions that inform effective treatment strategies. Leading companies in the biopsy devices sector—such as Boston Scientific Corporation, Cardinal Health, Medtronic, BD, Cook Medical, FUJIFILM, and Hologic Inc.—are driving continuous innovation and advancements within this dynamic healthcare market.

Biopsy Devices Market Insights

In 2022, North America led the global biopsy devices market and is expected to retain this leading position throughout the forecast period from 2025 to 2032. The rising prevalence of lung cancer, along with continuous technological innovations in biopsy devices, are major factors driving demand in the region.

The American Cancer Society reported in 2023 that the United States had approximately 236,740 new lung cancer cases in 2022. Since biopsy devices are essential for accurate lung cancer diagnosis, the increasing number of cases is anticipated to stimulate market growth.

Technological advancements in biopsy tools are also contributing to market expansion. For instance, in October 2020, GE Healthcare launched the Serena Bright contrast-enhanced guided biopsy solution in the U.S., designed to improve breast cancer outcomes. This technology enables clinicians to perform contrast-guided breast biopsies using existing mammography equipment and staff, enhancing procedural efficiency and patient care.

To know more about why North America is leading the market growth in the Biopsy Devices market, get a snapshot of the Biopsy Devices Market Outlook

Biopsy Devices Market Dynamics

A major factor driving the growth of the biopsy devices market is the increasing prevalence of breast cancer. According to the World Health Organization (WHO) 2021 report, 2.3 million women were diagnosed with breast cancer globally in 2020, with a cumulative 7.8 million cases recorded over the preceding five years. Biopsy devices are essential for accurately diagnosing breast cancer and guiding effective treatment, which in turn boosts demand and supports market growth between 2025 and 2032.

Another key contributor to market expansion is the rising geriatric population. WHO data from 2021 indicates that the global population aged 60 and above is expected to nearly double from 12% in 2015 to 22% by 2050, reaching 2.1 billion individuals. By 2032, approximately one in six people worldwide will be aged 60 or older, while the population aged 80 and above is projected to triple from 2020 to 2050, reaching 426 million. As aging increases the risk of conditions such as cancer, infections, and autoimmune disorders, the demand for biopsy devices rises, further fueling market growth.

Collectively, the growing incidence of breast cancer and the expanding elderly population are expected to drive strong demand for biopsy devices, propelling substantial growth in the global market during the forecast period from 2025 to 2032.

Biopsy Devices Market Drivers:

The biopsy devices market is witnessing consistent growth, fueled by factors including the rising incidence of breast cancer, an expanding aging population, increasing lung cancer cases, and continuous advancements in biopsy technology.

Get a sneak peek at the Biopsy Devices market dynamics @ https://www.delveinsight.com/sample-request/biopsy-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Coverage: Global

Study Period: 2022 to 2032

Key Biopsy Devices Companies: Boston Scientific Corporation, Cardinal Health, Medtronic, BD, Cook, Devicor Medical Products Inc, B. Braun Melsungen AG, ARGON MEDICAL, OLYMPUS CORPORATION, FUJIFILM, INRAD Inc, Hologic Inc, C. R. Bard, Dr. Japan Co Ltd, Limaca-medical, Owlstone Medical Ltd, Zamar Care, KOELIS, ST. STONE MEDICAL DEVICES PVT LTD, Iscon Surgicals Ltd, and others.

Which MedTech key players in the Biopsy Devices market are set to emerge as the trendsetter, explore @ Biopsy Devices Companies

Table of Contents

1. Biopsy Devices Market Report Introduction

2. Biopsy Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Biopsy Devices Market Key Factors Analysis

6. Biopsy Devices Market Porter’s Five Forces Analysis

7. Biopsy Devices Market Layout

8. Biopsy Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/